Examining Evidence Gaps and Ketogenic Diet in Epilepsy Care

A new review in The Lancet Neurology synthesizes clinical and mechanistic evidence supporting ketogenic diet therapies for epilepsy while highlighting persistent gaps in randomized trial data.¹ Although these dietary interventions have been used for over a century, study authors emphasize the evolution of their role in modern epilepsy care, particularly as interest grows in earlier use and broader clinical application.

Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycemic index treatment, have shown to reduce seizures in part by shifting cerebral metabolism from glucose to ketone bodies. This metabolic shift is associated with improvements in mitochondrial function, reduced neuroinflammation, and modulation of neurotransmitter systems, with emerging evidence also implicating the gut microbiome in antiseizure effects.¹

Reframing the Role of Ketogenic Diets in Epilepsy Care

The review is less notable for introducing a new efficacy signal than for reframing how ketogenic therapies may be positioned in care. Drug-resistant epilepsy, defined as failure of 2 appropriately chosen antiseizure medications, affects approximately 30% of patients and remains a major unmet need.¹

Across studies, ketogenic diet therapies demonstrated meaningful clinical benefit, with nearly half of patients achieving at least a 50% reduction in seizure frequency. Lead author Anna Figueroa, PharmD, PhD student at the University of Colorado, and colleagues suggest that particularly in pediatric populations and in metabolic epilepsies such as glucose transporter type 1 deficiency, earlier initiation may improve outcomes and potentially limit downstream neuronal and mitochondrial injury. However, experts stop short of recommending universal early use, citing limitations in the evidence base.¹

Clinical Evidence: Benefits With Important Caveats

Evidence from randomized controlled trials and meta-analyses suggested that ketogenic diet therapies can improve seizure control, particularly in children with drug-resistant epilepsy. In pediatric populations, these diets have been associated with higher rates of seizure reduction and, in some cases, seizure freedom compared with standard antiseizure medications.¹

However, the strength of this evidence remains limited. Many trials were small, heterogeneous, and of short duration, making it difficult to draw firm conclusions about long-term efficacy and safety. In adults, data were even more sparse, with few randomized trials and mixed findings regarding seizure outcomes and tolerability.

Comparative studies across dietary approaches suggest that while the classic ketogenic diet may offer slightly higher efficacy, less restrictive options, such as the modified Atkins diet and low glycemic index treatment, tend to have better tolerability and adherence. These trade-offs are clinically relevant, particularly in real-world settings where dietary burden can influence outcomes.

Implementation Considerations and Patient Selection

The review highlighted substantial variability in how ketogenic diet therapies are implemented in practice. According to the study authors, the classic ketogenic diet remains the most restrictive, typically requiring precise macronutrient ratios and close dietary supervision. In contrast, the modified Atkins diet and low glycemic index treatment offer greater flexibility and may be more feasible for adolescents, adults, and patients in resource-limited settings.

Diet selection should be individualized based on patient age, epilepsy etiology, comorbidities, and lifestyle factors. For example, the classic ketogenic diet is often preferred in younger children and in specific epilepsy syndromes, whereas less restrictive approaches may improve adherence in older patients.

Ketogenic therapies are typically initiated alongside antiseizure medications and may allow for medication reduction over time in some patients. However, careful monitoring is required due to potential adverse effects, including gastrointestinal symptoms, dyslipidemia, and micronutrient deficiencies, as well as possible drug–diet interactions.

Mechanistic Insights: Beyond a Single Pathway

Rather than acting through a single mechanism, ketogenic diet therapies appear to exert antiseizure effects through multiple, overlapping pathways. These include shifts in neurotransmitter balance toward increased inhibitory GABAergic activity, modulation of adenosine signaling, and improvements in mitochondrial energy metabolism.¹

The diets also appear to reduce oxidative stress and neuroinflammation while promoting mitochondrial resilience. Emerging research further suggests that alterations in the gut microbiome may contribute to seizure control by influencing metabolic and neurotransmitter pathways.

This mechanistic breadth may help explain why ketogenic therapies demonstrate benefit across diverse epilepsy etiologies, although the review does not identify validated biomarkers to guide patient selection.

Limitations of the Evidence Base

Despite encouraging clinical and mechanistic data, the authors emphasized that the overall certainty of evidence remains limited. Cochrane reviews and meta-analyses have consistently rated randomized controlled trial evidence for ketogenic diet therapies as low or very low certainty.¹

READ MORE: Survey Highlights Gaps in Epilepsy Treatment Expectations and Communication

Key limitations of the review included small sample sizes, heterogeneity in study design and dietary protocols, short follow-up periods, and challenges related to adherence and real-world implementation. These factors complicate comparisons across diet types and patient populations and limit generalizability.

Future Directions for Research and Clinical Use

The authors call for large-scale comparative effectiveness studies to better define the role of ketogenic diet therapies in epilepsy care. Future research should account for differences in age, epilepsy type, dietary modality, and sociodemographic factors, while also addressing real-world barriers such as adherence and access to care.

Additional priorities include identifying biomarkers to predict treatment response, standardizing outcome measures, and evaluating long-term safety. Mechanistic research may also support the development of pharmacologic therapies that replicate the beneficial effects of ketogenic diets with reduced patient burden.

References
1. Figeroa AG, Joshi CN, Patel MN. From clinical practice to mechanistic insights in ketogenic diets for epilepsy. Lancet Neurol. 2026;25(5):519-532. doi:10.1016/S1474-4422(26)00008-6